Vaxcyte Inc [PCVX] stock is trading at $89.29, up 14.27%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PCVX shares have gain 2.29% over the last week, with a monthly amount glided 1.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on December 20, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $135. Previously, Mizuho started tracking the stock with Buy rating on December 07, 2023, and set its price target to $69. On April 18, 2023, TD Cowen initiated with a Outperform rating. Needham reiterated its Buy rating and increased its price target to $58 on January 03, 2023. Guggenheim initiated its recommendation with a Buy and recommended $66 as its price target on December 15, 2022. BTIG Research started tracking with a Buy rating for this stock on November 17, 2022, and assigned it a price target of $69.
Vaxcyte Inc [PCVX] stock has fluctuated between $58.10 and $121.06 over the past year. Currently, Wall Street analysts expect the stock to reach $148.8 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $89.29 at the most recent close of the market. An investor can expect a potential return of 66.65% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
Gross Profit Margin for this corporation currently stands at 0.03% with Operating Profit Margin at -36.62%, Pretax Profit Margin comes in at -35.14%, and Net Profit Margin reading is -35.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.24 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 83.18 points at the first support level, and at 77.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 92.53, and for the 2nd resistance point, it is at 95.76.
Ratios To Look Out For
For context, Vaxcyte Inc’s Current Ratio is 17.88. As well, the Quick Ratio is 17.88, while the Cash Ratio is 8.48.
Transactions by insiders
Recent insider trading involved Loxam Teri, Director, that happened on Jan 15 ’25 when 6250.0 shares were purchased. SVP, GEN COUNSEL & CORP SEC, Eydelman Mikhail completed a deal on Jan 06 ’25 to sell 5000.0 shares. Meanwhile, Officer Eydelman Mikhail bought 5000.0 shares on Jan 06 ’25.
